Momentum: An M3 Employee Benefits Trend Report 2026

Employee Benefits

M3 has produced an annual employee benefits trend report for over 20 years — and each year, the story gets more complex. Last year, we reframed this report around a simple truth: the old playbook isn’t enough anymore. This year, that truth has only deepened.

In 2026, employers aren’t just watching costs rise, they’re fighting back. The data shows it. The strategies show it. The results, while still challenging, show early signs that active, informed employers are beginning to bend the curve.

But “beginning to bend” is not the same as “under control.” Health care costs remain at elevated levels of increase, and the forces driving them — cancer, behavioral health, specialty drugs, musculoskeletal conditions, and chronic disease — are not retreating. They are evolving. And so must your strategy.

Health care costs continue to rise year over year, creating growing pressure for employers and their workforce. While the drivers of this trend are complex, the financial impact is clear.

That number deserves context. On one hand, 7.46% represents a meaningful moderation from last year’s 8.64% average increase. On the other hand, it remains well above general inflation — and it comes on top of already elevated cost levels from prior years. The compounding effect matters: a 7.46% increase on a $17,042 base is a very different problem than a 7.46% increase would have been five years ago.

Employers are increasingly willing to make real plan changes adjusting designs, shifting funding models, deploying point solutions, and renegotiating pharmacy arrangements. The 2026 data reflects the early returns on that activity. Employers who leaned in are seeing results. Those who waited are still absorbing the full impact.

When looking at health care costs by employer size, the picture is nuanced:

Employer
Size
2025 Avg.
Increase
2026 Avg.
Increase
Direction
0–99
Enrolled
8.42% 7.35%
100–249
Enrolled
9.52% 7.76%
250–499
Enrolled
8.36% 6.24%
500+
Enrolled
8.91% 8.97%

Three of the four size bands improved year over year — a meaningful signal that employer action is having an effect. But one band stands out: employers with 500 or more enrolled employees saw their average increase climb to 8.97%. While not a dramatic reversal, it stands in contrast to the meaningful improvement seen across every other segment.

This is worth watching closely. Large employers often have greater self-funded exposure, more complex plan designs, and higher concentrations of high-cost claimants. The catastrophic claims story — particularly around cancer and specialty drugs — may be showing up most acutely in this segment. If you’re in this size band, the data is a signal to act with urgency, not wait for the market to stabilize.

Employers are navigating continued cost acceleration heading into 2027. But what’s actually driving these increases? The 2026 data points to five primary cost pressures  and importantly, they are not independent of one another. They interact, compound, and in many cases, share common solutions.

cancer ribbon icon

For catastrophic claims exceeding $100,000, cancer is the #1 condition among M3 clients  representing 25.9% of all high-cost claim spend. To put that in perspective, cancer spend is more than 3x that of the second highest catastrophic condition. No other diagnosis comes close.

Cancer has moved to the top of the cost driver list — not because it’s new, but because three forces are converging simultaneously: more frequent diagnoses, higher treatment costs (driven heavily by specialty medications), and longer treatment durations as survival rates improve. That last point is often overlooked. Better outcomes are genuinely good news — but they also mean more months of high-cost treatment per patient. Employers should expect cancer to remain the dominant catastrophic claims driver for the foreseeable future.

Behavioral and mental health spend increased an average of +9.1% year over year across M3’s book of business.

Utilization of mental health services continues to climb across all demographics, and the cost of those services is climbing even faster, driven by sharp increases in facility costs. The gap between demand and available providers remains wide, creating access challenges that delay care and, in many cases, allow conditions to worsen before treatment begins. When access is delayed, costs go up — deferred outpatient mental health care too often becomes inpatient psychiatric care, crisis intervention, or lost productivity that never shows up on a claims report but is felt throughout the organization.

A notable and growing sub-trend: dependent utilization. Mental health claims among employees’ dependents — particularly adolescents and young adults — are increasing at a rate that warrants its own strategic attention. Employers who are only thinking about employee mental health are missing a significant and growing portion of the spend.

Musculoskeletal conditions — particularly knee, joint, and back surgeries — are driving spend through a combination of increased outpatient surgical volume and elevated per-procedure costs. The shift to outpatient settings was supposed to reduce costs; in many cases, the savings have been offset by volume growth and facility fee inflation.

overview of today's cost pressures

M3 benchmark data shows specialty drugs now account for 51.5% of total spend, aligning closely with the 50–60% industry range. For the first time, the majority of what employers are spending on pharmacy is being driven by a relatively small number of high-cost medications.

That is even before accounting for GLP-1 medications which, importantly, are not classified as specialty drugs. They fall under the traditional drug bucket, meaning the 51.5% figure and the GLP-1 cost pressure are two separate and compounding challenges employers are managing simultaneously.

Specialty drug spend is driving trend in two distinct ways: through the pharmacy channel (high-cost oral and self-administered specialty medications) and through the medical channel (infusion drugs administered in clinical settings, often for cancer treatment). Many employers have focused their pharmacy optimization efforts on the pharmacy channel — but medical channel specialty drugs, particularly oncology infusions, represent a significant and often undermanaged cost center. Addressing both channels is essential.

showing cost pressures

More people. Higher costs. And a new medication category changing the math. The prevalence of chronic conditions – diabetes, hypertension, coronary artery disease, obesity – continues to grow, and the cost of managing them is rising alongside it. GLP-1 medications (Ozempic®, Wegovy®, and their successors) have added a new dimension to this challenge: they offer genuine clinical benefit for diabetes and weight management, but at a cost that can represent 3-5% of total healthcare spend (Med/Rx) OR between 10-20% of the Rx Spend. Employers are wrestling with how to cover these medications thoughtfully, balancing clinical value, member access, and long-term financial sustainability

Rather than waiting for cost pressure to ease, employers are actively reevaluating their benefits strategies — testing new models, fine-tuning existing ones, and stepping away from approaches that no longer deliver value. While no one strategy fits all, several trends are gaining momentum, some are holding steady, and others are declining in relevance.

Not every trend will be the right fit for your organization — and that’s the point. The most effective benefits strategies are those aligned with your population, goals, culture and risk tolerance. As you evaluate the options in this report, consider how these factors might shape your next move:

Point solutions are everywhere — but only some are actually solving the problems that matter. What’s changed in 2026 is the sophistication of how employers are selecting and deploying them.

The most successful implementations are no longer just grounded in current employer-specific data — they’re using predictive modeling to identify future cost drivers before they become catastrophic. This forward-looking approach allows employers to intervene earlier, improve outcomes, and deliver measurable ROI rather than simply reacting to last year’s claims.

With the right analytic tools, employers can pinpoint gaps, align investments accordingly, and measure what’s working.

To address cost and quality variation, employers are increasingly implementing narrow or tiered networks — and the approach is maturing.

  • Narrow networks limit provider choice to high-value options
  • Tiered networks steer members toward preferred providers through financial incentives

When paired with effective communication and employee engagement, these networks promote better consumer choices and reduce unnecessary spending. The key word is paired — network design without member education rarely delivers its full potential.

Employers are moving beyond traditional fee-for-service structures in pursuit of solutions that better align payment with outcomes — and in 2026, this movement has expanded in two meaningful directions.

Direct Primary Care (DPC) continues to grow in both geographic reach and flexibility of offerings. More employers can access DPC arrangements today than even a year ago, as providers expand into new markets and adapt their models to fit a wider range of employer sizes and structures. The core value proposition remains: a flat per-member-per-month payment that improves access, continuity, and affordability of primary care — while reducing downstream specialty and emergency utilization.

Targeted direct contracts for specific conditions are gaining traction as a complementary strategy. Rather than broad network arrangements, these contracts address the entire care bundle for high-cost conditions — establishing direct, upfront, negotiated costs for episodes of care. They are particularly effective in markets where provider concentration creates meaningful cost variation, and where a specific condition (such as orthopedic surgery or cardiac care) represents a disproportionate share of spend.

These benefit designs remove deductibles and coinsurance, replacing them with fixed copays that vary by provider or facility — rewarding employees who choose high-quality, lower-cost care.

What’s new in 2026: The number of administrators and plan sponsors offering variable copay designs has expanded, and so has their geographic footprint. This is no longer a strategy available only to large employers in major markets. More employers — across more geographies — can now access these designs than a year ago, making variable copay plans a more realistic option to evaluate than they’ve ever been.

As benefits ecosystems become more complex, employers are turning to advocacy and navigation solutions to guide employees through care decisions, claims issues, and provider selection.

When paired with strong communication and clinical integration, care navigation can improve the member experience while reducing unnecessary spend. In a year defined by complex cost drivers — cancer, behavioral health, specialty drugs — the value of a skilled navigator has never been higher.

Employers are increasingly acknowledging that factors outside the traditional health plan — transportation, housing, food access, language barriers — can significantly influence employee health outcomes and health care costs.

These efforts reflect a broader shift toward addressing whole-person health — and as data tools improve, the ability to identify and act on SDOH factors at the population level is growing.

Interest in onsite and nearsite care models remains steady, especially in industries with concentrated employee populations or limited provider access. These clinics can deliver:

  • Lower-cost, employer-controlled primary care
  • Integrated wellness and preventive services
  • Improved engagement for chronic condition support

Adoption has leveled off for some employers due to startup costs and challenges in driving sustained utilization — but for the right employer profile, these models continue to deliver meaningful value.

Programs built around step challenges, wellness portals, or health risk assessments continue to have a place in many organizations — particularly as entry points into broader wellness strategies. But these tools alone are no longer seen as innovative or leading-edge, especially when they lack clinical integration or measurable outcomes tied to individual progress.

Today, more employers are expanding their approach to focus on building a culture of health and supporting health care consumerism — emphasizing preventive care like age-appropriate screenings and primary care utilization. While ROI is difficult to quantify for general wellness efforts, value on investment (VOI) remains strong when programs are aligned with workforce needs, foster sustained engagement, and contribute to long-term risk mitigation. For chronic condition management programs, measurable ROI becomes more achievable through targeted, data-driven interventions.

While high-deductible health plans (HDHPs) remain a popular component of many benefit strategies, fewer employers are offering them as a standalone option.

Rising out-of-pocket costs have prompted renewed focus on affordability, leading to increased interest in copay-based, variable copay, or value-based designs that offer better upfront cost transparency and improved employee experience. The growth of variable copay plans — noted above — is in part a direct response to the limitations of HDHP-only strategies.